CD4+ T lymphocyte infiltration correlates with regression of a UV-induced squamous cell carcinoma.

Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

CD4+ T lymphocyte infiltration correlates with regression of a UV-induced squamous cell carcinoma.

J Dermatol Sci. 1995 Jan;9(1):12-9. Unique Identifier : AIDSLINE MED/95244405
Patel A; Halliday GM; Barnetson RS; Department of Dermatology, University of Sydney, Royal Prince; Alfred Hospital, Australia.

Abstract: It is currently unknown which arm of the immune system is responsible for regression of tumours. We have studied the T lymphocytes infiltrating a spontaneously regressing murine squamous cell carcinoma during the growth, plateau and regression phases of tumour development. In the plateau phase, where tumour growth is partially controlled by the immune system so that tumour size remains static, there was a considerable influx of CD4+ cells into the tumour. There was also an increase in the number of cells expressing the receptor for interleukin 2 (IL-2R), indicating that these cells were probably activated. The number of CD4+ cells remained high during the regression phase, where immunological destruction exceeded tumour growth. In contrast, CD8+ cells were only present in low numbers, and did not change during growth or regression of the tumours. These results indicate that CD4+ cells are probably responsible for tumour destruction. Thus CD4+ T lymphocytes are able to mediate tumour rejection and should be given more consideration for immunotherapy.

Keywords: Animal Carcinoma, Squamous Cell/ETIOLOGY/*IMMUNOLOGY/PATHOLOGY CD4-Positive T-Lymphocytes/*IMMUNOLOGY/PATHOLOGY CD8-Positive T-Lymphocytes/IMMUNOLOGY/PATHOLOGY Female Lymphocyte Count Mice Mice, Inbred HRS Neoplasm Regression, Spontaneous/*IMMUNOLOGY/PATHOLOGY Receptors, Interleukin-2/METABOLISM Skin Neoplasms/ETIOLOGY/*IMMUNOLOGY/PATHOLOGY T-Lymphocyte Subsets/IMMUNOLOGY/PATHOLOGY Time Factors Ultraviolet Rays/ADVERSE EFFECTS JOURNAL ARTICLE
950830
M9580985

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .